Metoclopramide Basi (Metoclopramide Hydrochloride Monohydrate)

Metoclopramide works by blocking dopamine D2 receptors in the brain’s chemoreceptor trigger zone, which reduces the sensation of nausea. In the gastrointestinal tract, it enhances acetylcholine release, stimulating smooth‑muscle contraction and accelerating gastric motility.

The appropriate dose of Metoclopramide Basi is determined by the prescribing clinician based on the patient’s condition, age, weight, and route of administration. Healthcare professionals set the regimen to achieve optimal therapeutic effect while minimizing risk.

Safety data for Metoclopramide in pregnancy and lactation are limited. Clinicians should assess the potential benefits against possible risks before prescribing to pregnant or nursing women, and use the lowest effective dose if treatment is deemed necessary.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Metoclopramide differs from agents like ondansetron, which target serotonin receptors, by primarily antagonising dopamine D2 receptors and enhancing gastric motility. It may be preferred when both anti‑emetic and pro‑kinetic effects are desired, whereas ondansetron is often chosen for its selective serotonin antagonism and lower extrapyramidal risk.

Metoclopramide Basi should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the product. If temperature excursions occur, consult the supplier before use.

Metoclopramide Basi is administered by intramuscular or intravenous injection under the supervision of a qualified healthcare professional. The route, rate, and duration are determined by the prescriber according to the clinical indication and patient response.

Serious risks include extrapyramidal reactions such as dystonia or tardive dyskinesia, neuroleptic malignant syndrome, severe allergic reactions, and cardiac arrhythmias. Patients should be monitored closely for these events, especially during high‑dose or prolonged therapy.

Metoclopramide Basi is contraindicated in individuals with known hypersensitivity to the drug, those with pheochromocytoma, and patients with gastrointestinal obstruction, perforation, or hemorrhage. Caution is also advised for patients with a history of movement disorders or severe depression.